IP Verse

Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of Cancer - EP3254695

The patent EP3254695 was granted to Astellas Pharma on Sep 9, 2020. The application was originally filed on May 21, 2013 under application number EP17171169A. The patent is currently recorded with a legal status of "Revoked".

EP3254695

ASTELLAS PHARMA
Application Number
EP17171169A
Filing Date
May 21, 2013
Status
Revoked
Feb 18, 2025
Grant Date
Sep 9, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

DR H ULRICH DORRIESJun 9, 2021DORRIESADMISSIBLE
DR H ULRICH DORRIESJun 9, 2021DORRIES, HANS ULRICH , DF-MP DORRIES FRANK-MOLNIA & POHLMANADMISSIBLE

Patent Citations (12) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0338841
DESCRIPTIONUS2003118592
DESCRIPTIONUS2003133939
DESCRIPTIONWO0243478
DESCRIPTIONWO2004035607
DESCRIPTIONWO8704462
DESCRIPTIONWO8901036
EXAMINATIONWO2008145338
OPPOSITIONWO2008145338
SEARCHUS2012020989
SEARCHWO2010009794
SEARCHWO2011090005

Non-Patent Literature (NPL) Citations (39) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- AMON ET AL., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", AMON ET AL., REISFELD ET AL., Monoclonal Antibodies And Cancer Therapy, ALAN R. LISS, INC., (1985), pages 243 - 56-
DESCRIPTION- "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", BALDWIN ET AL., Monoclonal Antibodies For Cancer Detection And Therapy, ACADEMIC PRESS, (1985), pages 303 - 16-
DESCRIPTION- BENNY K.C., LO ANTIBODY ENGINEERING-
DESCRIPTION- BIRD ET AL., SCIENCE, (1988), vol. 242, pages 423 - 426-
DESCRIPTION- FISCHER, R. ET AL., BIOL. CHEM, (1999), vol. 380, pages 825 - 839-
DESCRIPTION- GLENN E. MORRIS, EPITOPE MAPPING PROTOCOLS (METHODS IN MOLECULAR BIOLOGY-
DESCRIPTION- HELLSTROM ET AL., "Antibodies For Drug Delivery", HELLSTROM ET AL., ROBINSON ET AL., Controlled Drug Delivery (2nd Ed.), MARCEL DEKKER, INC., (1987), pages 623 - 53-
DESCRIPTION- HOLLIGER, P. ET AL., PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, pages 6444 - 6448-
DESCRIPTION- HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, (1988), vol. 85, pages 5879 - 5883-
DESCRIPTION- JONES, P. ET AL., NATURE, (1986), vol. 321, pages 522 - 525-
DESCRIPTION- KOHLER; MILSTEIN, NATURE, (1975), vol. 256, page 495-
DESCRIPTION- KRAUS ET AL., "Methods in Molecular Biology series", RECOMBINANT ANTIBODIES FOR CANCER THERAPY-
DESCRIPTION- MORRISON, S., SCIENCE, (1985), vol. 229, page 1202-
DESCRIPTION- NEDDLEMAN; WUNSCH, J. MOL. BIOL., (1970), vol. 48, page 443-
DESCRIPTION- OLWYN M. R. WESTWOOD; FRANK C. HAY, EPITOPE MAPPING: A PRACTICAL APPROACH, vol. 248-
DESCRIPTION- PEARSON; LIPMAN, PROC. NATL ACAD. SCI. USA, (1988), vol. 85, page 2444-
DESCRIPTION- POLJAK, R. J. ET AL., STRUCTURE, (1994), vol. 2, pages 1121 - 1123-
DESCRIPTION- POLLOCK ET AL., J. IMMUNOL. METH, (1999), vol. 231, pages 147 - 157-
DESCRIPTION- QUEEN, C. ET AL., PROC. NATL. ACAD. SCI. U. S. A., (1989), vol. 86, pages 10029 - 10033-
DESCRIPTION- RIECHMANN, L. ET AL., NATURE, (1998), vol. 332, pages 323 - 327-
DESCRIPTION- ROSSI ET AL., AM. J. CLIN. PATHOL., (2005), vol. 124, page 295-
DESCRIPTION- SCATCHARD ET AL., ANN N.Y. ACAD. SCL, (1949), vol. 51, page 660-
DESCRIPTION- SMITH; WATERMAN, ADS APP. MATH., (1981), vol. 2, page 482-
DESCRIPTION- SPIEKER-POLET ET AL., PROC. NATL. ACAD. SCI. U.S.A., (1995), vol. 92, page 9348-
DESCRIPTION- THORPE, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", THORPE, PINCHERAET AL., Monoclonal Antibodies '84: Biological And Clinical Applications, (1985), pages 475 - 506-
DESCRIPTION- VERMA, R. ET AL., J. IMMUNOL. METH, (1998), vol. 216, pages 165 - 181-
DESCRIPTION- WARD ET AL., NATURE, (1989), vol. 341, pages 544 - 546-
DESCRIPTION- WELSCHOF; KRAUS, RECOMBINANT ANTIBODES FOR CANCER THERAPY-
DESCRIPTION- ZITVOGEL L. ET AL., CELL, (2010), vol. 140, pages 798 - 804-
DESCRIPTION- THORPE ET AL., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", IMMUNOL. REV., (1982), vol. 62, doi:doi:10.1111/j.1600-065X.1982.tb00392.x, pages 119 - 58, XP001179872
EXAMINATION- Aristides Polyzos ET AL, "Subsets of Patients with Advanced Gastric Cancer Responding to Second-line Chemotherapy with Docetaxel - Cisplatin", Anticancer Research, Greece, (20060901), pages 3749 - 3754, URL: http://ar.iiarjournals.org/content/26/5B/3749.full.pdf#page=1&view=FitH, (20200114), XP055657695-
EXAMINATION- Ganymed Pharmaceuticals Gmbh, "Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal CancerNCT00909025", ClinicalTrials.gov, (20090327), URL: http://citenpl.internal.epo.org/wf/web/citenpl/citenpl.html, (20181115), XP055524253-
EXAMINATION- SAHIN UGUR ET AL, "Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20081201), vol. 14, no. 23, doi:10.1158/1078-0432.CCR-08-1547, ISSN 1078-0432, pages 7624 - 7634, XP002588324
OPPOSITION- Felice Pasini, Anna Paola Fraccon, Giovanni De Manzoni, "The Role of Chemotherapy in Metastatic Gastric Cancer", Anticancer Research, (20111000), vol. 31, no. 10, pages 3543 - 3554, XP055819153-
OPPOSITION- Ganymed Pharmaceuticals Gmbh, "Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal Cancer", Study Report from ClinicalTrials.gov for Clinical Trial NCT00909025, URL: https://clinicaltrials.gov/ct2/historv/NCT00909025?V8=View#StudyPageTop, XP055524253-
OPPOSITION- Beverly A. Teicher, Tumor Models in Cancer Research Second Edition, Springer Science+Business Media, LLC, (20110000), pages 106-113, 332-342, 571-587, 597 - 598, XP055819148
OPPOSITION- Ӧzlem Türeci; Mitnacht-Kraus Rita; Wöll Stefan; Yamada Tomohiro; Sahin Ugur, "Characterization of zolbetuximab in pancreatic cancer models", Oncoimmunology, (20181110), vol. 8, no. 1, page e1523096, XP055678806
OPPOSITION- Tetzlaff Eric, Ajani Jaffer, Cheng Jonathan, "Review of docetaxel in the treatment of gastric cancer", Therapeutics and Clinical Risk Management, (20081000), vol. 4, no. 5, pages 999 - 1007, XP055819157
SEARCH- KOBUNAI TAKASHI ET AL, "Antitumour Activity of S-1 in Combination with Cetuximab on Human Gastric Cancer Cell Lines In Vivo", ANTICANCER RESEARCH, (201111), vol. 31, no. 11, pages 3691 - 3696, XP002678607 [I] 1-36 * the whole document *-

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents